Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

NCT03865082 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Tilsotolimod
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Idera Pharmaceuticals, Inc.

Collaborators

[object Object]